On March 5, 2026, Lineage Cell Therapeutics detailed its progress evaluating the AlloSCOPE platform as a scalable off-the-shelf allogeneic cell therapy solution for islet transplantation in Type 1 diabetes. The technology enables manufacturing millions of doses from a single pluripotent cell line to address production scale challenges.

Lineage reached its first milestone under its worldwide collaboration with Roche, advancing the development of its islet cell therapy candidate. This achievement triggers predefined development activities and may unlock additional funding and support for late-stage preclinical studies.

Successful scaling of AlloSCOPE for islet cell therapy could position Lineage as a leading supplier of off-the-shelf diabetes treatments, potentially capturing market share in the growing cell therapy sector. Further data and regulatory updates are expected as the collaboration progresses toward clinical development.